Skip to main content
$4.55 -$0.07 (-1.5%)

04:00 PM EDT on 10/22/21

Epizyme (NASDAQ:EPZM)

CAPS Rating: No stars

Current Price $4.55 Mkt Cap $472.4M
Open $4.65 P/E Ratio 0.00
Prev. Close $4.55 Div. (Yield) $0.00 (0.0%)
Daily Range $4.45 - $4.65 Volume 816,089
52-Wk Range $4.28 - $14.30 Avg. Daily Vol. 809,911

Caps

How do you think NASDAQ:EPZM will perform against the market?

Add Stock to CAPS Watchlist

All Players

30 Outperform
6 Underperform
 

All-Star Players

8 Outperform
3 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:EPZM Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFEBCapital (96.86)
Submitted May 04, 2017

The company's making progress on developing drugs that interfere with gene expression, and results for its lead drug, tazemetostat, appear strong. It's being evaluated for use in molecularly defined solid tumors and non-Hodgkin lymphoma, and it's… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

NASDAQ:EPZM VS S&P 500 (SPY)

Fools bullish on NASDAQ:EPZM are also bullish on:

Fools bearish on NASDAQ:EPZM are also bearish on:

Recent Community Commentary

Read the most recent pitches from players about EPZM.

Recs

0
Member Avatar LazyHarlequin (85.11) Submitted: 8/2/2018 11:48:55 AM : Underperform Start Price: $9.00 NASDAQ:EPZM Score: +111.13

On 8/2/18 down $4.07 to $8.92. Options available for 2/15/19 with strike of $7.50.

Recs

1
Member Avatar TMFEBCapital (96.86) Submitted: 5/4/2017 12:04:27 PM : Outperform Start Price: $16.65 NASDAQ:EPZM Score: -163.10

The company's making progress on developing drugs that interfere with gene expression, and results for its lead drug, tazemetostat, appear strong. It's being evaluated for use in molecularly defined solid tumors and non-Hodgkin lymphoma, and it's currently in phase 2 studies in epithelioid sarcoma, relapsed/refractory diffuse large B-cell lymphoma (DLBCL) with an EZH2-activating mutation, and relapsed/refractory follicular lymphoma, regardless of EZH2 activation. If presentations at ASCO next month are well received, this company could have constructive conversations with the FDA over an approval pathway later this year.

Recs

0
Member Avatar sullyz0r (43.98) Submitted: 11/25/2014 10:06:33 PM : Outperform Start Price: $21.84 NASDAQ:EPZM Score: -197.96

First-mover advantage in the up and coming epigenetic oncology field. Probably will be ahead of its time, but that model has worked well for $ALNY.

Leaderboard

Find the members with the highest scoring picks in EPZM.

Score Leader

chris293

chris293 (24.74) Score: +261.41

The Score Leader is the player with the highest score across all their picks in EPZM.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
chris293 24.74 10/9/2013 Underperform 5Y $37.89 -88.10% +173.31% +261.41 1 Comment
ACMGresearch 23.65 6/3/2013 Underperform 5Y $25.04 -81.99% +178.30% +260.29 0 Comment
kevrose31 80.75 1/10/2014 Underperform 1Y $37.00 -87.81% +146.35% +234.16 0 Comment
jeepdrew2 44.70 12/5/2014 Underperform 5Y $21.76 -79.27% +118.00% +197.27 0 Comment
Novavm 94.45 8/3/2018 Underperform 5Y $9.90 -54.44% +60.39% +114.84 0 Comment
LazyHarlequin 85.11 8/2/2018 Underperform 5Y $9.00 -49.88% +61.25% +111.13 1 Comment
Hobooda < 20 5/24/2021 Outperform 5Y $8.78 -48.63% +8.58% -57.21 0 Comment
PAGEBOY2020 93.31 11/13/2020 Outperform 5Y $11.73 -61.55% +27.17% -88.72 0 Comment
drugtrader 83.37 11/11/2020 Outperform 5Y $12.00 -62.40% +26.82% -89.22 0 Comment
WarCapital 40.82 9/10/2018 Outperform 5Y $10.15 -55.57% +56.94% -112.51 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for EPZM.